[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fWRoRSW-rLW8text76GraOY9nWP7qgrUADjRezxBhSRc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":46,"rows":53},"University of Leicester",[4],165,false,34,8,16242953,2,137,[14,17,20,23,25,27,30,33],{"name":15,"count":16},"Diabetes Mellitus, Type 2",13,{"name":18,"count":19},"Cardiovascular Diseases",9,{"name":21,"count":22},"Asthma",7,{"name":24,"count":22},"Type 2 Diabetes",{"name":26,"count":22},"Coronary Artery Disease",{"name":28,"count":29},"Heart Failure",6,{"name":31,"count":32},"Peripheral Arterial Disease",5,{"name":34,"count":32},"Chronic Kidney Diseases",[36,41],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04663204","A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy","2025-03-31","Sparsentan",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05887271","A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction","2026-05-31","Low calorie meal replacement plan",[47,48,49,50,51,52],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[54,81,108,148,171,189,207,231,259,287,305,323,341,359,432,459,490,516,542,564,586,608,630,648,674,692,710,728,746,764,793,811,829,847,865,891,918,936,962,980,998,1016,1042,1066,1091,1116,1139,1166,1191,1217],{"intervention":45,"totalTrials":55,"cells":56},1,{"EARLY_PHASE1":57,"PHASE1":60,"PHASE2":62,"PHASE3":64,"PHASE4":77,"NA":79},{"trials":58,"activeCount":59},[],0,{"trials":61,"activeCount":59},[],{"trials":63,"activeCount":59},[],{"trials":65,"activeCount":55,"soonestReadout":44},[66],{"nctId":42,"briefTitle":43,"status":67,"phases":68,"primaryCompletion":44,"completion":44,"start":69,"enrollment":70,"conditions":71,"interventions":76},"RECRUITING",[49,50],"2023-12-05",63,[72,73,15,74,75],"Heart Failure With Preserved Ejection Fraction","Heart Failure, Diastolic","Diabetes Mellitus Type 2 in Obese","Obesity Adult Onset",[45],{"trials":78,"activeCount":59},[],{"trials":80,"activeCount":59},[],{"intervention":40,"totalTrials":55,"cells":82},{"EARLY_PHASE1":83,"PHASE1":85,"PHASE2":87,"PHASE3":102,"PHASE4":104,"NA":106},{"trials":84,"activeCount":59},[],{"trials":86,"activeCount":59},[],{"trials":88,"activeCount":55,"soonestReadout":39},[89],{"nctId":37,"briefTitle":38,"status":90,"phases":91,"primaryCompletion":39,"completion":39,"start":92,"enrollment":93,"conditions":94,"interventions":101},"ACTIVE_NOT_RECRUITING",[49],"2020-12-10",12,[95,96,97,98,99,100],"Immunoglobulin A Nephropathy","Kidney Diseases","Glomerulonephritis, IGA","Glomerulonephritis","Autoimmune Diseases","Immune System Diseases",[40],{"trials":103,"activeCount":59},[],{"trials":105,"activeCount":59},[],{"trials":107,"activeCount":59},[],{"intervention":109,"totalTrials":11,"cells":110},"Liraglutide",{"EARLY_PHASE1":111,"PHASE1":113,"PHASE2":115,"PHASE3":117,"PHASE4":133,"NA":146},{"trials":112,"activeCount":59},[],{"trials":114,"activeCount":59},[],{"trials":116,"activeCount":59},[],{"trials":118,"activeCount":59},[119],{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":131},"NCT02043054","Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","COMPLETED",[50],"2017-09-02","2017-09-29","2013-12-16",90,[129,130],"Type 2 Diabetes Mellitus","Cardiovascular Disease",[109,132],"Sitagliptin",{"trials":134,"activeCount":59},[135],{"nctId":136,"briefTitle":137,"status":122,"phases":138,"primaryCompletion":139,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":143},"NCT02292290","Trial for People With Established Type 2 Diabetes During Ramadan",[51],"2012-12","2011-04",99,[24],[109,109,144,145],"Sulfonylurea or Pioglitazone","Maintain dual therapy (Sulf\u002FPio) as comparator to Liraglutide",{"trials":147,"activeCount":59},[],{"intervention":149,"totalTrials":55,"cells":150},"IMP oral",{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":159,"NA":169},{"trials":152,"activeCount":59},[],{"trials":154,"activeCount":59},[],{"trials":156,"activeCount":59},[],{"trials":158,"activeCount":59},[],{"trials":160,"activeCount":59},[161],{"nctId":162,"briefTitle":163,"status":122,"phases":164,"primaryCompletion":165,"completion":165,"start":166,"enrollment":19,"conditions":167,"interventions":168},"NCT04219124","The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes",[51],"2020-01-08","2018-09-20",[24],[149],{"trials":170,"activeCount":59},[],{"intervention":144,"totalTrials":55,"cells":172},{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":179,"PHASE4":181,"NA":187},{"trials":174,"activeCount":59},[],{"trials":176,"activeCount":59},[],{"trials":178,"activeCount":59},[],{"trials":180,"activeCount":59},[],{"trials":182,"activeCount":59},[183],{"nctId":136,"briefTitle":137,"status":122,"phases":184,"primaryCompletion":139,"completion":139,"start":140,"enrollment":141,"conditions":185,"interventions":186},[51],[24],[109,109,144,145],{"trials":188,"activeCount":59},[],{"intervention":145,"totalTrials":55,"cells":190},{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":197,"PHASE4":199,"NA":205},{"trials":192,"activeCount":59},[],{"trials":194,"activeCount":59},[],{"trials":196,"activeCount":59},[],{"trials":198,"activeCount":59},[],{"trials":200,"activeCount":59},[201],{"nctId":136,"briefTitle":137,"status":122,"phases":202,"primaryCompletion":139,"completion":139,"start":140,"enrollment":141,"conditions":203,"interventions":204},[51],[24],[109,109,144,145],{"trials":206,"activeCount":59},[],{"intervention":208,"totalTrials":55,"cells":209},"Empagliflozin",{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":229},{"trials":211,"activeCount":59},[],{"trials":213,"activeCount":59},[],{"trials":215,"activeCount":59},[],{"trials":217,"activeCount":59},[],{"trials":219,"activeCount":59},[220],{"nctId":221,"briefTitle":222,"status":122,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":228},"NCT02798744","SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.",[51],"2019-07-30","2016-12",68,[15],[208],{"trials":230,"activeCount":59},[],{"intervention":232,"totalTrials":55,"cells":233},"Saxenda",{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":242,"NA":257},{"trials":235,"activeCount":59},[],{"trials":237,"activeCount":59},[],{"trials":239,"activeCount":59},[],{"trials":241,"activeCount":59},[],{"trials":243,"activeCount":59},[244],{"nctId":245,"briefTitle":246,"status":122,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":256},"NCT03036800","Saxenda in Obesity Services (STRIVE Study)",[51],"2021-02-28","2022-02-25","2017-11-28",392,[253,254,255],"Obesity","Weight Loss","Diabetes Mellitus",[232],{"trials":258,"activeCount":59},[],{"intervention":260,"totalTrials":55,"cells":261},"Canagliflozin",{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":270,"NA":285},{"trials":263,"activeCount":59},[],{"trials":265,"activeCount":59},[],{"trials":267,"activeCount":59},[],{"trials":269,"activeCount":59},[],{"trials":271,"activeCount":59},[272],{"nctId":273,"briefTitle":274,"status":122,"phases":275,"primaryCompletion":276,"completion":276,"start":277,"enrollment":278,"conditions":279,"interventions":280},"NCT02694263","Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan",[51],"2018-09-13","2016-07",25,[15],[260,281,282,283,284],"Repaglinide","Pioglitazone","Gliclazide","Glimepiride",{"trials":286,"activeCount":59},[],{"intervention":281,"totalTrials":55,"cells":288},{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":303},{"trials":290,"activeCount":59},[],{"trials":292,"activeCount":59},[],{"trials":294,"activeCount":59},[],{"trials":296,"activeCount":59},[],{"trials":298,"activeCount":59},[299],{"nctId":273,"briefTitle":274,"status":122,"phases":300,"primaryCompletion":276,"completion":276,"start":277,"enrollment":278,"conditions":301,"interventions":302},[51],[15],[260,281,282,283,284],{"trials":304,"activeCount":59},[],{"intervention":282,"totalTrials":55,"cells":306},{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":313,"PHASE4":315,"NA":321},{"trials":308,"activeCount":59},[],{"trials":310,"activeCount":59},[],{"trials":312,"activeCount":59},[],{"trials":314,"activeCount":59},[],{"trials":316,"activeCount":59},[317],{"nctId":273,"briefTitle":274,"status":122,"phases":318,"primaryCompletion":276,"completion":276,"start":277,"enrollment":278,"conditions":319,"interventions":320},[51],[15],[260,281,282,283,284],{"trials":322,"activeCount":59},[],{"intervention":283,"totalTrials":55,"cells":324},{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":339},{"trials":326,"activeCount":59},[],{"trials":328,"activeCount":59},[],{"trials":330,"activeCount":59},[],{"trials":332,"activeCount":59},[],{"trials":334,"activeCount":59},[335],{"nctId":273,"briefTitle":274,"status":122,"phases":336,"primaryCompletion":276,"completion":276,"start":277,"enrollment":278,"conditions":337,"interventions":338},[51],[15],[260,281,282,283,284],{"trials":340,"activeCount":59},[],{"intervention":284,"totalTrials":55,"cells":342},{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":351,"NA":357},{"trials":344,"activeCount":59},[],{"trials":346,"activeCount":59},[],{"trials":348,"activeCount":59},[],{"trials":350,"activeCount":59},[],{"trials":352,"activeCount":59},[353],{"nctId":273,"briefTitle":274,"status":122,"phases":354,"primaryCompletion":276,"completion":276,"start":277,"enrollment":278,"conditions":355,"interventions":356},[51],[15],[260,281,282,283,284],{"trials":358,"activeCount":59},[],{"intervention":360,"totalTrials":32,"cells":361},"vincristine sulfate",{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":368,"PHASE4":428,"NA":430},{"trials":363,"activeCount":59},[],{"trials":365,"activeCount":59},[],{"trials":367,"activeCount":59},[],{"trials":369,"activeCount":59},[370,385,392,403,416],{"nctId":371,"briefTitle":372,"status":373,"phases":374,"start":375,"enrollment":376,"conditions":377,"interventions":379},"NCT00047138","Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor","UNKNOWN",[50],"2001-01",350,[378],"Kidney Cancer",[380,381,382,383,384,360],"dactinomycin","carboplatin","cyclophosphamide","doxorubicin hydrochloride","etoposide",{"nctId":386,"briefTitle":387,"status":373,"phases":388,"start":389,"enrollment":376,"conditions":390,"interventions":391},"NCT00003804","Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor",[50],"1993-07",[378],[380,360],{"nctId":393,"briefTitle":394,"status":373,"phases":395,"start":396,"enrollment":397,"conditions":398,"interventions":400},"NCT00053872","Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma",[50],"2003-02",316,[399],"Brain and Central Nervous System Tumors",[401,402,360],"cisplatin","lomustine",{"nctId":404,"briefTitle":405,"status":373,"phases":406,"primaryCompletion":407,"start":408,"enrollment":409,"conditions":410,"interventions":412},"NCT00020566","Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and\u002For Surgery in Treating Patients With Ewing's Sarcoma",[50],"2011-12","2001-02",1200,[411],"Sarcoma",[380,413,383,384,414,415,360],"busulfan","ifosfamide","melphalan",{"nctId":417,"briefTitle":418,"status":373,"phases":419,"start":420,"enrollment":421,"conditions":422,"interventions":424},"NCT00030719","Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma",[50],"2001-12",175,[423],"Neuroblastoma",[425,426,413,381,382,384,427,415,360],"filgrastim","monoclonal antibody Ch14.18","isotretinoin",{"trials":429,"activeCount":59},[],{"trials":431,"activeCount":59},[],{"intervention":380,"totalTrials":433,"cells":434},3,{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":441,"PHASE4":455,"NA":457},{"trials":436,"activeCount":59},[],{"trials":438,"activeCount":59},[],{"trials":440,"activeCount":59},[],{"trials":442,"activeCount":59},[443,447,451],{"nctId":371,"briefTitle":372,"status":373,"phases":444,"start":375,"enrollment":376,"conditions":445,"interventions":446},[50],[378],[380,381,382,383,384,360],{"nctId":386,"briefTitle":387,"status":373,"phases":448,"start":389,"enrollment":376,"conditions":449,"interventions":450},[50],[378],[380,360],{"nctId":404,"briefTitle":405,"status":373,"phases":452,"primaryCompletion":407,"start":408,"enrollment":409,"conditions":453,"interventions":454},[50],[411],[380,413,383,384,414,415,360],{"trials":456,"activeCount":59},[],{"trials":458,"activeCount":59},[],{"intervention":381,"totalTrials":433,"cells":460},{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":476,"PHASE4":486,"NA":488},{"trials":462,"activeCount":59},[],{"trials":464,"activeCount":59},[],{"trials":466,"activeCount":59},[467],{"nctId":468,"briefTitle":469,"status":373,"phases":470,"start":471,"enrollment":472,"conditions":473,"interventions":475},"NCT00077389","Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma",[49],"2004-01",57,[474],"Liver Cancer",[381,401,383],{"trials":477,"activeCount":59},[478,482],{"nctId":371,"briefTitle":372,"status":373,"phases":479,"start":375,"enrollment":376,"conditions":480,"interventions":481},[50],[378],[380,381,382,383,384,360],{"nctId":417,"briefTitle":418,"status":373,"phases":483,"start":420,"enrollment":421,"conditions":484,"interventions":485},[50],[423],[425,426,413,381,382,384,427,415,360],{"trials":487,"activeCount":59},[],{"trials":489,"activeCount":59},[],{"intervention":383,"totalTrials":433,"cells":491},{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":502,"PHASE4":512,"NA":514},{"trials":493,"activeCount":59},[],{"trials":495,"activeCount":59},[],{"trials":497,"activeCount":59},[498],{"nctId":468,"briefTitle":469,"status":373,"phases":499,"start":471,"enrollment":472,"conditions":500,"interventions":501},[49],[474],[381,401,383],{"trials":503,"activeCount":59},[504,508],{"nctId":371,"briefTitle":372,"status":373,"phases":505,"start":375,"enrollment":376,"conditions":506,"interventions":507},[50],[378],[380,381,382,383,384,360],{"nctId":404,"briefTitle":405,"status":373,"phases":509,"primaryCompletion":407,"start":408,"enrollment":409,"conditions":510,"interventions":511},[50],[411],[380,413,383,384,414,415,360],{"trials":513,"activeCount":59},[],{"trials":515,"activeCount":59},[],{"intervention":384,"totalTrials":433,"cells":517},{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":524,"PHASE4":538,"NA":540},{"trials":519,"activeCount":59},[],{"trials":521,"activeCount":59},[],{"trials":523,"activeCount":59},[],{"trials":525,"activeCount":59},[526,530,534],{"nctId":371,"briefTitle":372,"status":373,"phases":527,"start":375,"enrollment":376,"conditions":528,"interventions":529},[50],[378],[380,381,382,383,384,360],{"nctId":404,"briefTitle":405,"status":373,"phases":531,"primaryCompletion":407,"start":408,"enrollment":409,"conditions":532,"interventions":533},[50],[411],[380,413,383,384,414,415,360],{"nctId":417,"briefTitle":418,"status":373,"phases":535,"start":420,"enrollment":421,"conditions":536,"interventions":537},[50],[423],[425,426,413,381,382,384,427,415,360],{"trials":539,"activeCount":59},[],{"trials":541,"activeCount":59},[],{"intervention":382,"totalTrials":11,"cells":543},{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":550,"PHASE4":560,"NA":562},{"trials":545,"activeCount":59},[],{"trials":547,"activeCount":59},[],{"trials":549,"activeCount":59},[],{"trials":551,"activeCount":59},[552,556],{"nctId":371,"briefTitle":372,"status":373,"phases":553,"start":375,"enrollment":376,"conditions":554,"interventions":555},[50],[378],[380,381,382,383,384,360],{"nctId":417,"briefTitle":418,"status":373,"phases":557,"start":420,"enrollment":421,"conditions":558,"interventions":559},[50],[423],[425,426,413,381,382,384,427,415,360],{"trials":561,"activeCount":59},[],{"trials":563,"activeCount":59},[],{"intervention":401,"totalTrials":11,"cells":565},{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":576,"PHASE4":582,"NA":584},{"trials":567,"activeCount":59},[],{"trials":569,"activeCount":59},[],{"trials":571,"activeCount":59},[572],{"nctId":468,"briefTitle":469,"status":373,"phases":573,"start":471,"enrollment":472,"conditions":574,"interventions":575},[49],[474],[381,401,383],{"trials":577,"activeCount":59},[578],{"nctId":393,"briefTitle":394,"status":373,"phases":579,"start":396,"enrollment":397,"conditions":580,"interventions":581},[50],[399],[401,402,360],{"trials":583,"activeCount":59},[],{"trials":585,"activeCount":59},[],{"intervention":413,"totalTrials":11,"cells":587},{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":594,"PHASE4":604,"NA":606},{"trials":589,"activeCount":59},[],{"trials":591,"activeCount":59},[],{"trials":593,"activeCount":59},[],{"trials":595,"activeCount":59},[596,600],{"nctId":404,"briefTitle":405,"status":373,"phases":597,"primaryCompletion":407,"start":408,"enrollment":409,"conditions":598,"interventions":599},[50],[411],[380,413,383,384,414,415,360],{"nctId":417,"briefTitle":418,"status":373,"phases":601,"start":420,"enrollment":421,"conditions":602,"interventions":603},[50],[423],[425,426,413,381,382,384,427,415,360],{"trials":605,"activeCount":59},[],{"trials":607,"activeCount":59},[],{"intervention":415,"totalTrials":11,"cells":609},{"EARLY_PHASE1":610,"PHASE1":612,"PHASE2":614,"PHASE3":616,"PHASE4":626,"NA":628},{"trials":611,"activeCount":59},[],{"trials":613,"activeCount":59},[],{"trials":615,"activeCount":59},[],{"trials":617,"activeCount":59},[618,622],{"nctId":404,"briefTitle":405,"status":373,"phases":619,"primaryCompletion":407,"start":408,"enrollment":409,"conditions":620,"interventions":621},[50],[411],[380,413,383,384,414,415,360],{"nctId":417,"briefTitle":418,"status":373,"phases":623,"start":420,"enrollment":421,"conditions":624,"interventions":625},[50],[423],[425,426,413,381,382,384,427,415,360],{"trials":627,"activeCount":59},[],{"trials":629,"activeCount":59},[],{"intervention":402,"totalTrials":55,"cells":631},{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":638,"PHASE4":644,"NA":646},{"trials":633,"activeCount":59},[],{"trials":635,"activeCount":59},[],{"trials":637,"activeCount":59},[],{"trials":639,"activeCount":59},[640],{"nctId":393,"briefTitle":394,"status":373,"phases":641,"start":396,"enrollment":397,"conditions":642,"interventions":643},[50],[399],[401,402,360],{"trials":645,"activeCount":59},[],{"trials":647,"activeCount":59},[],{"intervention":649,"totalTrials":55,"cells":650},"Mepolizumab",{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":657,"PHASE4":670,"NA":672},{"trials":652,"activeCount":59},[],{"trials":654,"activeCount":59},[],{"trials":656,"activeCount":59},[],{"trials":658,"activeCount":59},[659],{"nctId":660,"briefTitle":661,"status":122,"phases":662,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":666,"interventions":669},"NCT04075331","Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial",[49,50],"2024-06-21","2020-09-07",238,[667,668],"COPD","Eosinophilia",[649],{"trials":671,"activeCount":59},[],{"trials":673,"activeCount":59},[],{"intervention":414,"totalTrials":55,"cells":675},{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":682,"PHASE4":688,"NA":690},{"trials":677,"activeCount":59},[],{"trials":679,"activeCount":59},[],{"trials":681,"activeCount":59},[],{"trials":683,"activeCount":59},[684],{"nctId":404,"briefTitle":405,"status":373,"phases":685,"primaryCompletion":407,"start":408,"enrollment":409,"conditions":686,"interventions":687},[50],[411],[380,413,383,384,414,415,360],{"trials":689,"activeCount":59},[],{"trials":691,"activeCount":59},[],{"intervention":132,"totalTrials":55,"cells":693},{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":700,"PHASE4":706,"NA":708},{"trials":695,"activeCount":59},[],{"trials":697,"activeCount":59},[],{"trials":699,"activeCount":59},[],{"trials":701,"activeCount":59},[702],{"nctId":120,"briefTitle":121,"status":122,"phases":703,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":704,"interventions":705},[50],[129,130],[109,132],{"trials":707,"activeCount":59},[],{"trials":709,"activeCount":59},[],{"intervention":425,"totalTrials":55,"cells":711},{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":724,"NA":726},{"trials":713,"activeCount":59},[],{"trials":715,"activeCount":59},[],{"trials":717,"activeCount":59},[],{"trials":719,"activeCount":59},[720],{"nctId":417,"briefTitle":418,"status":373,"phases":721,"start":420,"enrollment":421,"conditions":722,"interventions":723},[50],[423],[425,426,413,381,382,384,427,415,360],{"trials":725,"activeCount":59},[],{"trials":727,"activeCount":59},[],{"intervention":426,"totalTrials":55,"cells":729},{"EARLY_PHASE1":730,"PHASE1":732,"PHASE2":734,"PHASE3":736,"PHASE4":742,"NA":744},{"trials":731,"activeCount":59},[],{"trials":733,"activeCount":59},[],{"trials":735,"activeCount":59},[],{"trials":737,"activeCount":59},[738],{"nctId":417,"briefTitle":418,"status":373,"phases":739,"start":420,"enrollment":421,"conditions":740,"interventions":741},[50],[423],[425,426,413,381,382,384,427,415,360],{"trials":743,"activeCount":59},[],{"trials":745,"activeCount":59},[],{"intervention":427,"totalTrials":55,"cells":747},{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":754,"PHASE4":760,"NA":762},{"trials":749,"activeCount":59},[],{"trials":751,"activeCount":59},[],{"trials":753,"activeCount":59},[],{"trials":755,"activeCount":59},[756],{"nctId":417,"briefTitle":418,"status":373,"phases":757,"start":420,"enrollment":421,"conditions":758,"interventions":759},[50],[423],[425,426,413,381,382,384,427,415,360],{"trials":761,"activeCount":59},[],{"trials":763,"activeCount":59},[],{"intervention":765,"totalTrials":55,"cells":766},"Rucaparib",{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":787,"PHASE4":789,"NA":791},{"trials":768,"activeCount":59},[],{"trials":770,"activeCount":59},[],{"trials":772,"activeCount":59},[773],{"nctId":774,"briefTitle":775,"status":373,"phases":776,"primaryCompletion":777,"completion":777,"start":778,"enrollment":779,"conditions":780,"interventions":782},"NCT03654833","Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma",[49],"2023-10-31","2019-01-28",186,[781],"Mesothelioma, Malignant",[765,783,784,785,786],"Abemaciclib","pembrolizumab & bemcentinib","Atezolizumab & Bevacizumab","Dostarlimab and Niraparib",{"trials":788,"activeCount":59},[],{"trials":790,"activeCount":59},[],{"trials":792,"activeCount":59},[],{"intervention":783,"totalTrials":55,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":805,"PHASE4":807,"NA":809},{"trials":796,"activeCount":59},[],{"trials":798,"activeCount":59},[],{"trials":800,"activeCount":59},[801],{"nctId":774,"briefTitle":775,"status":373,"phases":802,"primaryCompletion":777,"completion":777,"start":778,"enrollment":779,"conditions":803,"interventions":804},[49],[781],[765,783,784,785,786],{"trials":806,"activeCount":59},[],{"trials":808,"activeCount":59},[],{"trials":810,"activeCount":59},[],{"intervention":784,"totalTrials":55,"cells":812},{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":823,"PHASE4":825,"NA":827},{"trials":814,"activeCount":59},[],{"trials":816,"activeCount":59},[],{"trials":818,"activeCount":59},[819],{"nctId":774,"briefTitle":775,"status":373,"phases":820,"primaryCompletion":777,"completion":777,"start":778,"enrollment":779,"conditions":821,"interventions":822},[49],[781],[765,783,784,785,786],{"trials":824,"activeCount":59},[],{"trials":826,"activeCount":59},[],{"trials":828,"activeCount":59},[],{"intervention":785,"totalTrials":55,"cells":830},{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":841,"PHASE4":843,"NA":845},{"trials":832,"activeCount":59},[],{"trials":834,"activeCount":59},[],{"trials":836,"activeCount":59},[837],{"nctId":774,"briefTitle":775,"status":373,"phases":838,"primaryCompletion":777,"completion":777,"start":778,"enrollment":779,"conditions":839,"interventions":840},[49],[781],[765,783,784,785,786],{"trials":842,"activeCount":59},[],{"trials":844,"activeCount":59},[],{"trials":846,"activeCount":59},[],{"intervention":786,"totalTrials":55,"cells":848},{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":859,"PHASE4":861,"NA":863},{"trials":850,"activeCount":59},[],{"trials":852,"activeCount":59},[],{"trials":854,"activeCount":59},[855],{"nctId":774,"briefTitle":775,"status":373,"phases":856,"primaryCompletion":777,"completion":777,"start":778,"enrollment":779,"conditions":857,"interventions":858},[49],[781],[765,783,784,785,786],{"trials":860,"activeCount":59},[],{"trials":862,"activeCount":59},[],{"trials":864,"activeCount":59},[],{"intervention":866,"totalTrials":55,"cells":867},"Sodium Valproate",{"EARLY_PHASE1":868,"PHASE1":870,"PHASE2":872,"PHASE3":885,"PHASE4":887,"NA":889},{"trials":869,"activeCount":59},[],{"trials":871,"activeCount":59},[],{"trials":873,"activeCount":59},[874],{"nctId":875,"briefTitle":876,"status":373,"phases":877,"primaryCompletion":878,"completion":878,"start":879,"enrollment":880,"conditions":881,"interventions":884},"NCT03825250","The Val-CARD Trial",[48,49],"2024-10-07","2018-11-06",122,[882,26,883],"Cardiac Valve Disease","Organ Failure, Multiple",[866],{"trials":886,"activeCount":59},[],{"trials":888,"activeCount":59},[],{"trials":890,"activeCount":59},[],{"intervention":892,"totalTrials":55,"cells":893},"Oral complex C3 curcumin + chemotherapy",{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":912,"PHASE4":914,"NA":916},{"trials":895,"activeCount":59},[],{"trials":897,"activeCount":59},[],{"trials":899,"activeCount":59},[900],{"nctId":901,"briefTitle":902,"status":122,"phases":903,"primaryCompletion":904,"completion":904,"start":905,"enrollment":906,"conditions":907,"interventions":910},"NCT01490996","Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer",[48,49],"2017-05-31","2012-02",41,[908,909],"Colonic Cancer","Metastasis",[892,911],"Chemotherapy only",{"trials":913,"activeCount":59},[],{"trials":915,"activeCount":59},[],{"trials":917,"activeCount":59},[],{"intervention":911,"totalTrials":55,"cells":919},{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":924,"PHASE3":930,"PHASE4":932,"NA":934},{"trials":921,"activeCount":59},[],{"trials":923,"activeCount":59},[],{"trials":925,"activeCount":59},[926],{"nctId":901,"briefTitle":902,"status":122,"phases":927,"primaryCompletion":904,"completion":904,"start":905,"enrollment":906,"conditions":928,"interventions":929},[48,49],[908,909],[892,911],{"trials":931,"activeCount":59},[],{"trials":933,"activeCount":59},[],{"trials":935,"activeCount":59},[],{"intervention":937,"totalTrials":55,"cells":938},"FOLFOX regimen",{"EARLY_PHASE1":939,"PHASE1":941,"PHASE2":943,"PHASE3":956,"PHASE4":958,"NA":960},{"trials":940,"activeCount":59},[],{"trials":942,"activeCount":59},[],{"trials":944,"activeCount":59},[945],{"nctId":946,"briefTitle":947,"status":373,"phases":948,"start":949,"conditions":950,"interventions":952},"NCT00004206","Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer",[49],"1999-09",[951],"Ovarian Cancer",[937,953,954,955],"fluorouracil","leucovorin calcium","oxaliplatin",{"trials":957,"activeCount":59},[],{"trials":959,"activeCount":59},[],{"trials":961,"activeCount":59},[],{"intervention":953,"totalTrials":55,"cells":963},{"EARLY_PHASE1":964,"PHASE1":966,"PHASE2":968,"PHASE3":974,"PHASE4":976,"NA":978},{"trials":965,"activeCount":59},[],{"trials":967,"activeCount":59},[],{"trials":969,"activeCount":59},[970],{"nctId":946,"briefTitle":947,"status":373,"phases":971,"start":949,"conditions":972,"interventions":973},[49],[951],[937,953,954,955],{"trials":975,"activeCount":59},[],{"trials":977,"activeCount":59},[],{"trials":979,"activeCount":59},[],{"intervention":954,"totalTrials":55,"cells":981},{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":992,"PHASE4":994,"NA":996},{"trials":983,"activeCount":59},[],{"trials":985,"activeCount":59},[],{"trials":987,"activeCount":59},[988],{"nctId":946,"briefTitle":947,"status":373,"phases":989,"start":949,"conditions":990,"interventions":991},[49],[951],[937,953,954,955],{"trials":993,"activeCount":59},[],{"trials":995,"activeCount":59},[],{"trials":997,"activeCount":59},[],{"intervention":955,"totalTrials":55,"cells":999},{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1010,"PHASE4":1012,"NA":1014},{"trials":1001,"activeCount":59},[],{"trials":1003,"activeCount":59},[],{"trials":1005,"activeCount":59},[1006],{"nctId":946,"briefTitle":947,"status":373,"phases":1007,"start":949,"conditions":1008,"interventions":1009},[49],[951],[937,953,954,955],{"trials":1011,"activeCount":59},[],{"trials":1013,"activeCount":59},[],{"trials":1015,"activeCount":59},[],{"intervention":1017,"totalTrials":55,"cells":1018},"MSTT1041A",{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1023,"PHASE3":1036,"PHASE4":1038,"NA":1040},{"trials":1020,"activeCount":59},[],{"trials":1022,"activeCount":59},[],{"trials":1024,"activeCount":59},[1025],{"nctId":1026,"briefTitle":1027,"status":122,"phases":1028,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":1032,"conditions":1033,"interventions":1035},"NCT03615040","Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP)",[49],"2020-05-29","2020-12-31","2018-10-11",81,[1034],"COPD Exacerbation",[1017],{"trials":1037,"activeCount":59},[],{"trials":1039,"activeCount":59},[],{"trials":1041,"activeCount":59},[],{"intervention":1043,"totalTrials":55,"cells":1044},"pegylated liposomal doxorubicin hydrochloride",{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1049,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1046,"activeCount":59},[],{"trials":1048,"activeCount":59},[],{"trials":1050,"activeCount":59},[1051],{"nctId":1052,"briefTitle":1053,"status":373,"phases":1054,"start":1055,"conditions":1056,"interventions":1059},"NCT00004236","Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer",[49],"1998-08",[1057,1058],"Esophageal Cancer","Gastric Cancer",[1043],{"trials":1061,"activeCount":59},[],{"trials":1063,"activeCount":59},[],{"trials":1065,"activeCount":59},[],{"intervention":1067,"totalTrials":55,"cells":1068},"aspirin and atorvastatin",{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1085,"PHASE4":1087,"NA":1089},{"trials":1070,"activeCount":59},[],{"trials":1072,"activeCount":59},[],{"trials":1074,"activeCount":59},[1075],{"nctId":1076,"briefTitle":1077,"status":373,"phases":1078,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":1082,"interventions":1084},"NCT04181749","Peri-vascular Adipose Tissue Inflammation Evaluated Using Coronary CT Angiography",[49],"2024-01-31","2020-11-18",200,[1083],"Cardiovascular Risk Factor",[1067],{"trials":1086,"activeCount":59},[],{"trials":1088,"activeCount":59},[],{"trials":1090,"activeCount":59},[],{"intervention":1092,"totalTrials":55,"cells":1093},"Sildenafil",{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1108,"PHASE3":1110,"PHASE4":1112,"NA":1114},{"trials":1095,"activeCount":59},[],{"trials":1097,"activeCount":59},[1098],{"nctId":1099,"briefTitle":1100,"status":122,"phases":1101,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":1105,"interventions":1107},"NCT02136329","A Study to Determine the Pharmacokinetic Profile, Safety and Tolerability of Sildenafil (REVATIO®) in Cardiac Surgery",[48],"2014-12","2013-06",36,[1106],"Acute Kidney Injury",[1092],{"trials":1109,"activeCount":59},[],{"trials":1111,"activeCount":59},[],{"trials":1113,"activeCount":59},[],{"trials":1115,"activeCount":59},[],{"intervention":1117,"totalTrials":55,"cells":1118},"liposomal daunorubicin citrate",{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1131,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1120,"activeCount":59},[],{"trials":1122,"activeCount":59},[1123],{"nctId":1124,"briefTitle":1125,"status":373,"phases":1126,"start":1127,"conditions":1128,"interventions":1130},"NCT00004207","Liposomal Daunorubicin in Treating Patients With Metastatic Breast Cancer",[48],"1997-12",[1129],"Breast Cancer",[1117],{"trials":1132,"activeCount":59},[],{"trials":1134,"activeCount":59},[],{"trials":1136,"activeCount":59},[],{"trials":1138,"activeCount":59},[],{"intervention":1140,"totalTrials":55,"cells":1141},"Influenza vaccination at different time points",{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1148,"PHASE4":1150,"NA":1152},{"trials":1143,"activeCount":59},[],{"trials":1145,"activeCount":59},[],{"trials":1147,"activeCount":59},[],{"trials":1149,"activeCount":59},[],{"trials":1151,"activeCount":59},[],{"trials":1153,"activeCount":59},[1154],{"nctId":1155,"briefTitle":1156,"status":122,"phases":1157,"primaryCompletion":1158,"completion":1159,"start":1160,"enrollment":1161,"conditions":1162,"interventions":1165},"NCT04570904","Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness",[],"2021-05-30","2021-09-01","2020-09-28",470,[1163,1164],"Influenza","Influenza -Like Illness",[1140],{"intervention":1167,"totalTrials":55,"cells":1168},"Congenital heart surgery",{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1170,"activeCount":59},[],{"trials":1172,"activeCount":59},[],{"trials":1174,"activeCount":59},[],{"trials":1176,"activeCount":59},[],{"trials":1178,"activeCount":59},[],{"trials":1180,"activeCount":59},[1181],{"nctId":1182,"briefTitle":1183,"status":122,"phases":1184,"primaryCompletion":1185,"completion":1185,"start":1186,"enrollment":1187,"conditions":1188,"interventions":1190},"NCT04992793","Paediatric Brain Injury Following Cardiac Interventions",[],"2024-11-01","2021-09-09",38,[1189],"Congenital Heart Disease",[1167],{"intervention":1192,"totalTrials":55,"cells":1193},"Vitamin D3 cholecalciferol",{"EARLY_PHASE1":1194,"PHASE1":1196,"PHASE2":1198,"PHASE3":1200,"PHASE4":1202,"NA":1204},{"trials":1195,"activeCount":59},[],{"trials":1197,"activeCount":59},[],{"trials":1199,"activeCount":59},[],{"trials":1201,"activeCount":59},[],{"trials":1203,"activeCount":59},[],{"trials":1205,"activeCount":59},[1206],{"nctId":1207,"briefTitle":1208,"status":1209,"phases":1210,"primaryCompletion":1211,"completion":1211,"start":1212,"enrollment":433,"conditions":1213,"interventions":1216},"NCT01385345","Vitamin D Replacement in Insulin Resistant South Asians","TERMINATED",[52],"2014-01","2012-08",[1214,1215],"Vitamin D Deficiency","Insulin Resistance",[1192],{"intervention":1218,"totalTrials":55,"cells":1219},"WES",{"EARLY_PHASE1":1220,"PHASE1":1222,"PHASE2":1224,"PHASE3":1226,"PHASE4":1228,"NA":1230},{"trials":1221,"activeCount":59},[],{"trials":1223,"activeCount":59},[],{"trials":1225,"activeCount":59},[],{"trials":1227,"activeCount":59},[],{"trials":1229,"activeCount":59},[],{"trials":1231,"activeCount":59},[1232],{"nctId":1233,"briefTitle":1234,"status":373,"phases":1235,"primaryCompletion":1236,"completion":1236,"start":1237,"enrollment":1238,"conditions":1239,"interventions":1243},"NCT03861741","A Study to Evaluate the Feasibility of Screening Relatives of Patients Affected by Non-Syndromic Thoracic Aortic Diseases",[52],"2022-05-20","2019-03-01",70,[1240,1241,1242],"Screening","Aortic Aneurysm and Dissection","Genetic Disease",[1218]]